Pillar Biosciences Strengthens Leadership Team with Appointment of Vincent Ricci as Chief Financial Officer
NATICK, Mass. – June 8, 2022 – (BUSINESS WIRE) – Pillar Biosciences, the leader in Decision Medicine™, which develops and distributes next-generation sequencing (NGS) tests to localize testing and reduce time to treatment initiation and overall testing costs, today announced the appointment of Vincent Ricci as Chief Financial Officer. Mr. Ricci will lead Pillar Bioscience’s […]
Pillar Biosciences Announces Online Publication of Data in the Journal of Clinical Oncology
Study entitled “Reducing Pre-analytical Sample QC Failure Rates for Cancer Molecular Genetic Assays with SLIMamp® Technology” published in conjunction with the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting NATICK, Mass. – May 31, 2022 – (BUSINESS WIRE) – Pillar Biosciences, the leader in Decision Medicine™, which develops and distributes next-generation sequencing […]
Pillar Biosciences Presents New Clinical Validation Data Confirming the Accuracy of its oncoReveal™ Dx Lung & Colon Cancer Assay in Detecting Clinically Relevant Variants
– Laboratory and software validation testing determined ability to accurately identify key companion diagnostic targets within KRAS and EGFR genes, and specify associated approved therapy – These data, plus three additional studies, presented at the 2022 American Association for Cancer Research (AACR) Annual Meeting NATICK, Mass. – April 11, 2022 – (BUSINESS WIRE) – Pillar […]
Pillar Biosciences Expands Leadership Team with Appointment of Daniel Harma as Chief Commercial Officer and Christa Adkins as General Counsel
NATICK, Mass. – March 8, 2022 – (BUSINESS WIRE) – Pillar Biosciences, an innovative, next-generation sequencing (NGS) solutions, in-vitro diagnostics (IVD) company, today announced the appointment of Daniel Harma, M.B.A., as Chief Commercial Officer and Christa Adkins, J.D., as General Counsel. Both executives join Pillar Biosciences with more than 20 years of experience in their […]
Pillar Biosciences to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
NATICK, Mass. – February 10, 2022 – (BUSINESS WIRE) – Pillar Biosciences, an innovative, next-generation sequencing (NGS) solutions, in-vitro diagnostics (IVD) company, today announced that Randy Pritchard, Chief Executive Officer, will present virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 16, 2022, at 12:30pm Eastern Time. About […]
Pillar Biosciences Receives CLIA Certification for its Next-Generation Sequencing Clinical Laboratory
NATICK, Mass. – January 6, 2022 – (BUSINESS WIRE) – Pillar Biosciences, an innovative, next-generation sequencing (NGS) solutions, in-vitro diagnostics (IVD) company, today announced that its NGS laboratory, located in Natick, Massachusetts, has passed the onsite inspection and received Clinical Laboratory Improvement Amendment (CLIA) certification from the U.S. Department of Health and Human Services’ Centers […]
Pillar Biosciences seeks to make precision medicine a first-line therapy for cancer patients
Randy Pritchard, Pillar Biosciences CEO, highlighted some of the progress the oncology solutions company has made in developing in-vitro diagnostics, in response to emailed questions from MedCity News. Why did you join Pillar Biosciences? I am incredibly impressed with the technology and the amazing team at Pillar that have done so much work to bring our oncoReveal™ Dx […]
Pillar Biosciences to Collaborate with Labcorp on Precision Genomic Cancer Testing Using Next-Generation Sequencing
NATICK, Mass.–(BUSINESS WIRE)– Pillar Biosciences, an innovative, next-generation sequencing (NGS) solutions, in-vitro diagnostics company, today announced that it has entered into an agreement with Labcorp (NYSE:LH), a leading global life sciences company, to provide genomic testing for people with cancer. Under the agreement, Pillar Biosciences will provide the oncoReveal™ Essential Myeloproliferative Neoplasm (MPN) panel. Using […]
Pillar Biosciences Announces Appointment of Randy Pritchard as Chief Executive Officer
NATICK, Mass. & SHANGHAI–(BUSINESS WIRE)– Pillar Biosciences, an innovative next-generation sequencing (NGS) solutions in-vitro diagnostics (IVD) company, today announced the appointment of Randy Pritchard as Chief Executive Officer. The company’s founder, industry veteran and renowned scientific innovator, Gang Song, Ph.D., will transition to the role of Chairman of the Board, where he will be responsible […]
XING Genomic Services receives NATA accreditation for Pillar Biosciences HRD Gene Panel Enabling Cost-Effective PARPi-response Prediction
Brisbane, Australia–XING Genomic Services, a subsidiary of XING Technologies, is pleased to announce that they have received NATA accreditation effective from July 2021 to offer clinical cancer genetic testing using the Pillar Biosciences HRD (homologous recombination deficiency) assay. This test identifies cancer patients that have tumours with impaired DNA repair capability, making them more likely […]